Jounce Therapeutics Inc. (Nasdaq: JNCE) reported a loss for the fourth quarter but the company reported that it was on track to file an Investigational New Drug for JTX-4014 in 2018. The stock price surged $4.24 to close at $26.08.
Jounce Therapeutics on track to file IND in 2018
March 08, 2018 at 16:05 PM EST
